Tarsus Q3 net loss $22.5M; NDA accepted for TP-03 with PDUFA Aug 2023

Tarsus Pharmaceuticals, Inc.

2022-Q3 EPS reported -$2.03 revenue$15,816,000

Net loss of $22.5M in Q3 2022 vs $15.7M in Q3 2021; R&D expense $10.9M, G&A $12.0M.
Cash and marketable securities $226.6M at Sep 30, 2022; runway into at least 2026.
FDA accepted TP-03 NDA for Demodex blepharitis; PDUFA target action date Aug 25, 2023.
Board changes: Scott Morrison appointed Audit Chair; Chairman Ackermann to depart; CEO Azamian expected to become Chairman.
Expected $30M milestones from LianBio out-license: $10M Dec 2022, $5M Q1 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tarsus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $0, net income $22.5 million.

Period: the third quarter ended September 30, 2022
Revenue: $0
Net income: $22.5 million
Result: reported results

Exact text from the filing

to net loss of $15.7 million for the same period in 2021 • Third quarter 2022 license fee and collaboration revenue, as part of the strategic partnership with LianBio, was $0, compared to $1.2 million for the same period in 2021 • Third quarter research and development expenses for 2022 were $10.9 million (inclusive of stock-based compensation of

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tarsus Pharmaceuticals, Inc. reported the third quarter ended September 30, 2022 results: revenue $0, net income $22.5 million.

Period: the third quarter ended September 30, 2022
Revenue: $0
Net income: $22.5 million
Result: reported results

Exact text from the filing

Third quarter 2022 license fee and collaboration revenue, as part of the strategic partnership with LianBio, was $0

View on SEC.gov

Browse all earnings releases →

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001819790-22-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.